U.S. Pharmaceuticals & Biotech Price disconnect

Gilead Sciences

Market Cap: US$161.2b

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Bristol-Myers Squibb

Market Cap: US$117.6b

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

Zoetis

Market Cap: US$31.7b

Engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.

United Therapeutics

Market Cap: US$23.2b

Engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

Neurocrine Biosciences

Market Cap: US$17.8b

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

Exelixis

Market Cap: US$14.2b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

Krystal Biotech

Market Cap: US$10.8b

A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.

TG Therapeutics

Market Cap: US$8.1b

A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

ACADIA Pharmaceuticals

Market Cap: US$4.5b

A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

Catalyst Pharmaceuticals

Market Cap: US$3.9b

A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.

Aurinia Pharmaceuticals

Market Cap: US$2.0b

A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.

Phibro Animal Health

Market Cap: US$1.3b

Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.

Collegium Pharmaceutical

Market Cap: US$1.1b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

Rigel Pharmaceuticals

Market Cap: US$787.3m

A biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.

CorMedix

Market Cap: US$659.0m

A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

Compugen

Market Cap: US$226.1m

A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.

Protalix BioTherapeutics

Market Cap: US$196.6m

A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.

Spero Therapeutics

Market Cap: US$121.6m

A clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.

Fortress Biotech

Market Cap: US$109.6m

Operates as a biopharmaceutical company in the United States and internationally.